New twists in the AXL(e) of tumor progression

Balazs Halmos, Eric B. Haura

Research output: Contribution to journalArticle

6 Scopus citations


Patients with a mesenchymal subtype of ovarian cancer face a poor prognosis with limited treatment options to halt metastatic progression. In this issue of Science Signaling, Antony et al. found that the kinase AXL drives the mesenchymal gene signature and motility of ovarian tumor cells. AXL inhibitors may thus slow tumor progression in this subset of patients. 2016

Original languageEnglish (US)
Article numberfs14
JournalScience Signaling
Issue number448
Publication statusPublished - Oct 4 2016


ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this